Istvan Lang

Summary

Publications

  1. doi request reprint Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response
    Zsolt Horvath
    Department of Chemotherapy B and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
    Pathol Oncol Res 17:541-50. 2011
  2. ncbi request reprint [Role of MRI in determining the therapy of rectal cancer]
    Eva Jederán
    Radiológiai Diagnosztikai Osztály, Országos Onkológiai Intézet, Budapest, Hungary
    Magy Onkol 56:179-86. 2012
  3. doi request reprint [Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer]
    Zoltan Matrai
    Altalános és Mellkassebészeti Osztály, Országos Onkológiai Intézet, Budapest, Hungary
    Magy Onkol 55:73-84. 2011
  4. doi request reprint Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
    Istvan Lang
    Department of Medical Oncology and Clinical Pharmacology B, National Institute of Oncology, Budapest, Hungary
    Eur J Cancer 49:439-48. 2013
  5. doi request reprint Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab
    Barna Budai
    National Institute of Oncology, Semmelweis University, Budapest, Hungary
    Pharmacogenet Genomics 22:69-72. 2012
  6. doi request reprint Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia
    Gábor Rubovszky
    National Institute of Oncology, Budapest, Hungary
    Pathol Oncol Res 19:119-22. 2013
  7. ncbi request reprint Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil
    Erika Hitre
    National Institute of Oncology, Budapest, Hungary
    Pharmacogenet Genomics 15:723-30. 2005
  8. doi request reprint Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
    Istvan Lang
    National Institute of Oncology, Budapest, Hungary
    Lancet Oncol 14:125-33. 2013
  9. ncbi request reprint Case 3. Resection of originally inoperable liver metastases of gastrointestinal stromal tumor after imatinib mesylate therapy
    Istvan Lang
    Department of Medical Oncology, National Institute of Oncology, Budapest, Hungary
    J Clin Oncol 21:3538-40. 2003
  10. ncbi request reprint Significance of histomorphology of early triple-negative breast cancer
    Gábor Rubovszky
    National Institute of Oncology, Budapest, Hungary
    Pathol Oncol Res 18:823-31. 2012

Detail Information

Publications15

  1. doi request reprint Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response
    Zsolt Horvath
    Department of Chemotherapy B and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
    Pathol Oncol Res 17:541-50. 2011
    ..Six cycles of CT could be enough for patients achieving CR, however sequential pre- and/or postoperative CT with non cross-resistant drugs should be considered for non-responders...
  2. ncbi request reprint [Role of MRI in determining the therapy of rectal cancer]
    Eva Jederán
    Radiológiai Diagnosztikai Osztály, Országos Onkológiai Intézet, Budapest, Hungary
    Magy Onkol 56:179-86. 2012
    ..The current role of multidetector computer tomography is for detecting distant metastasis and in local tumor staging of advanced cancers...
  3. doi request reprint [Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer]
    Zoltan Matrai
    Altalános és Mellkassebészeti Osztály, Országos Onkológiai Intézet, Budapest, Hungary
    Magy Onkol 55:73-84. 2011
    ..In the present paper the authors review the results and possible limitations of sentinel lymph node biopsy in relation to neoadjuvant chemotherapy...
  4. doi request reprint Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
    Istvan Lang
    Department of Medical Oncology and Clinical Pharmacology B, National Institute of Oncology, Budapest, Hungary
    Eur J Cancer 49:439-48. 2013
    ..Quality of life (QoL) was assessed, and associations with tumour response and survival were investigated...
  5. doi request reprint Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab
    Barna Budai
    National Institute of Oncology, Semmelweis University, Budapest, Hungary
    Pharmacogenet Genomics 22:69-72. 2012
    ..Bevacizumab-related hypertension might be a predictive marker of treatment efficacy (P=0.0002 for OS) in the case of wild (CC) SHMT1 1420 genotypes only...
  6. doi request reprint Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia
    Gábor Rubovszky
    National Institute of Oncology, Budapest, Hungary
    Pathol Oncol Res 19:119-22. 2013
    ..This case suggests that electrohyperthermia can probably be incorporated in palliative therapy added not only to radiotherapy or chemotherapy but also to anti-angiogenic BEV treatment...
  7. ncbi request reprint Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil
    Erika Hitre
    National Institute of Oncology, Budapest, Hungary
    Pharmacogenet Genomics 15:723-30. 2005
    ....
  8. doi request reprint Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial
    Istvan Lang
    National Institute of Oncology, Budapest, Hungary
    Lancet Oncol 14:125-33. 2013
    ..We compared the efficacy of the two regimens...
  9. ncbi request reprint Case 3. Resection of originally inoperable liver metastases of gastrointestinal stromal tumor after imatinib mesylate therapy
    Istvan Lang
    Department of Medical Oncology, National Institute of Oncology, Budapest, Hungary
    J Clin Oncol 21:3538-40. 2003
  10. ncbi request reprint Significance of histomorphology of early triple-negative breast cancer
    Gábor Rubovszky
    National Institute of Oncology, Budapest, Hungary
    Pathol Oncol Res 18:823-31. 2012
    ..For DFS perivascular invasion also showed significant effect (p = <0.042 HR:2.5 [1.0-6.0]). Nodal status was the strongest prognostic parameter but other histomorphologic parameters can be used for prognosis prediction...
  11. doi request reprint [Role of PET/CT in diagnosis and treatment of breast cancer -- review of present knowledge and perspectives for future research]
    Balázs Madaras
    Országos Onkológiai Intézet, B Belyógyászati, Onkológiai és Klinikai Farkológiai Osztály, Budapest, Hungary
    Magy Onkol 56:23-9. 2012
    ..We discuss the development of new radiotracers and their value in predicting treatment response, identifying tumor subtypes and finding new therapeutic targets by them...
  12. doi request reprint [Challenges in oncologic plastic surgery of the breast]
    Zoltan Matrai
    Altalános és Mellkassebészeti Osztály, Országos Onkológiai Intézet, Budapest, Hungary
    Magy Onkol 55:40-52. 2011
    ..Modern procedures differ both in concept and technique from that of traditional breast surgery. This paper provides a comprehensive and detailed overview of reconstructive and oncoplastic breast surgery...
  13. ncbi request reprint Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC)
    Katalin Boer
    V Department of Internal Medicine Oncology, Szent Margit Hospital, Budapest, H 1032, Hungary
    Pathol Oncol Res 9:166-9. 2003
    ..This benefit with TAC was seen regardless of hormone receptor status. Additional follow up data will evaluate the role of TAC in the adjuvant setting of early breast cancer treatment...
  14. ncbi request reprint [Possibilities and results with Herceptin-Taxol combination in the treatment of breast cancer]
    Istvan Lang
    Kemoterápia B Belgyógyászati Onkológiai Osztály, Országos Onkológiai Intézet, Budapest, 1122, Hungary
    Magy Onkol 46:195-6. 2002
    ..Based on these evidences the Herceptin-Taxol combined treatment protocol was introduced in Hungary for the treatment of Stage IV breast cancer patients...
  15. ncbi request reprint [BOLERO - another remarkable step in treatment of breast cancer]
    Gábor Rubovszky
    B Belgyógyászati Onkológiai és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary
    Magy Onkol 58:128-32. 2014
    ..4 month benefit in the experimental arm is clinically important but it has not reached the level of statistical significance. We have not had biomarkers so far that could help us to identify a subgroup of cancers sensitive to everolimus. ..